What is 'Orphan Drug Credit'

The orphan drug credit is a federal tax credit available to businesses, not individuals, that gives pharmaceutical companies incentives to develop medications and treatments for rare diseases that do not affect enough people for the company to be able to make a profit on the sales of those treatments to the patient population.

BREAKING DOWN 'Orphan Drug Credit'

The orphan drug credit is a credit available to pharmaceutical companies to create financial incentives to develop medications and treatments for rare diseases that affect small populations. This credit can be claimed by the pharmaceutical company whether testing to develop the treatments is performed by the company itself or contracted out to third parties. With some exceptions, testing must occur in the United States. Orphan drugs are drugs developed to treat orphan diseases, which is the group term for extremely rare medical conditions such as Huntington's Disease, ALS and Tourette Syndrome. 

Despite being rare conditions individually, orphan diseases affect a large number of people. Although there are almost 30 million people suffering from orphan diseases in the United States, there are only approved treatments for four percent of those diseases. This means that patients with 96 percent of orphan diseases have no good treatment options. The orphan drug tax credit is an effort to encourage the development of treatments for these diseases to give relief to the patients affected by them. Without these tax credits, pharmaceutical companies would be forced to charge prices for the treatments that are so high that the affected patients could never afford them, which would defeat the purpose of developing these treatments in the first place. The orphan drug tax credit bridges this gap and helps the companies develop the treatments while allowing them to be reasonably-enough priced that the people who need them can afford them.

History of Orphan Drug Credit

Before the Orphan Drug Act was passed in 1983, pharmaceutical companies and medical researchers were unable and unwilling to invest in treatments for extremely rare diseases, because they knew developing these treatments would never pay for themselves. There simply aren't enough patients of each orphan disease to be able to recoup their expenses, let along make a profit. Clinical trials cost thousands of dollars per patient even when the researchers could find enough patients to run these trials. They were unable to develop these treatments without a sponsor for the treatment development process, and many treatments sat waiting for a sponsor.

Between 1983 and 2018, the orphan drug tax credit gave a credit of 50 percent of the clinical testing costs for drugs being tested under section 505(i) of the Federal Food, Drug and Cosmetic Act. Part of the overhaul of the tax code conducted in 2017 during the Trump administration reduced the amount of the orphan drug tax credit from 50 percent to 25 percent of qualified clinical testing expenses beginning in 2018. This was seen as harmful by the National Organization for Rare Disorders and many other advocacy groups.

RELATED TERMS
  1. Drug

    A drug is a substance that cures, treats, prevents or reduces ...
  2. Corporate Orphan

    A corporate orphan is business unit or division that loses strategic ...
  3. Clinical Trials

    Clinical trials are studies of human volunteers for the purpose ...
  4. Food And Drug Administration (FDA)

    The Food and Drug Administration is a government agency that ...
  5. Pharmacovigilance

    Pharmacovigilance refers to the scientific process through which ...
  6. Dread Disease Rider

    A dread disease rider gives a percentage of the insurance death ...
Related Articles
  1. Investing

    Orphan Drug Rules Are Being Manipulated

    It may be the time to revamp the Orphan Drug Program amid concerns it's turning into a scam.
  2. Investing

    Opko Gets Orphan Status for Genetic Disorder Drug

    Opko’s neurological disorder drug CUR-1916 qualifies for many benefits under orphan drug status.
  3. Insights

    How Pharmaceutical Companies Price Their Drugs

    Learn more about how pharmaceutical companies price drugs, why prices are often very high and why it can be difficult to settle on a suitable price.
  4. Managing Wealth

    6 Common Conditions With Expensive Medications

    While the most expensive drugs may be for rare diseases, there are lots of common conditions that require some pricey prescriptions.
  5. Investing

    A Biotech Sector Primer

    Investing in biotechs can involve both huge losses and major gains. Learn about the industry that focuses on novel drug development and clinical research.
  6. Investing

    Evaluating Pharmaceutical Companies

    Learn how to find a healthy pharmaceutical investment in a market full of weak drugs.
  7. Investing

    Using DCF In Biotech Valuation

    Valuing firms in this sector can seem like a black art, but there is a systematic way to pin a price on potential.
  8. Investing

    Pharma Balks at German Price Control (BAYRY, RHHBY)

    Drug makers are worried about a proposed new German law that would tighten price controls on prescription drugs.
  9. Investing

    aTyr Pharma Rises 16% on Orphan Drug Status

    Atyr Pharma was granted orphan drug status for its Resolaris muscular dystrophy drug.
  10. Insights

    8 Stages Of New Drug Development

    Understanding biotech data isn't easy. What is a clinical trial, what are the various phases, and why do the results of these trials and applications often create double-digit moves in the price ...
RELATED FAQS
  1. What does it mean to have orphan drug status?

    The USDA incentivizes pharmaceutical companies to develop cures for rare diseases via the Office of Orphan Product Development. ... Read Answer >>
  2. Can your insurance company drug test you?

    Learn why drug companies conduct drug tests and how a lifestyle free of drugs and alcohol can save you big money on health ... Read Answer >>
  3. What are the major barriers to entry for new companies in the drugs sector?

    Find out why barriers to entry for U.S. drug companies are so high and how the Food and Drug Administration, or FDA, inhibits ... Read Answer >>
  4. Who are Pfizer's (PFE) main competitors?

    Learn about Pfizer's place in the pharmaceutical industry, and find out which major drug manufacturers are among its main ... Read Answer >>
  5. Biotech vs Pharmaceutical company

    Though biotech and pharmaceutical companies share similar business features, there also have differences. Here, we'll distinguish ... Read Answer >>
  6. Who are Gilead Sciences' (GILD) main competitors?

    Learn about the pharmaceutical company Gilead Sciences and its main competitors. Explore the company's role in creating HIV-preventing ... Read Answer >>
Hot Definitions
  1. Yield Curve

    A yield curve is a line that plots the interest rates, at a set point in time, of bonds having equal credit quality, but ...
  2. Portfolio

    A portfolio is a grouping of financial assets such as stocks, bonds and cash equivalents, also their mutual, exchange-traded ...
  3. Gross Profit

    Gross profit is the profit a company makes after deducting the costs of making and selling its products, or the costs of ...
  4. Diversification

    Diversification is the strategy of investing in a variety of securities in order to lower the risk involved with putting ...
  5. Intrinsic Value

    Intrinsic value is the perceived or calculated value of a company, including tangible and intangible factors, and may differ ...
  6. Current Assets

    Current assets is a balance sheet item that represents the value of all assets that can reasonably expected to be converted ...
Trading Center